Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine plus standard-dose versus low-dose venetoclax in elderly newly treated AML patients unfit for chemotherapy
ChiCTR2400084836Phase 4Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of azacitidine and venetoclax in acute myeloid leukemia (AML) (2 arms), sponsored by Beijing Hospital. Primary endpoint: Composite complete remission rate. Planned start May 2024; status: not yet recruiting.
02
Drugs
azacitidinevenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2400084836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084836.